RU2310445C2 - Применение гидроксиолеиновой кислоты и родственных соединений при производстве лекарственных средств - Google Patents

Применение гидроксиолеиновой кислоты и родственных соединений при производстве лекарственных средств Download PDF

Info

Publication number
RU2310445C2
RU2310445C2 RU2004114229/15A RU2004114229A RU2310445C2 RU 2310445 C2 RU2310445 C2 RU 2310445C2 RU 2004114229/15 A RU2004114229/15 A RU 2004114229/15A RU 2004114229 A RU2004114229 A RU 2004114229A RU 2310445 C2 RU2310445 C2 RU 2310445C2
Authority
RU
Russia
Prior art keywords
acid
proteins
hydroxyoleic
hydroxyoleic acid
compounds
Prior art date
Application number
RU2004114229/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2004114229A (ru
Inventor
РУИС Пабло Висенте ЭСКРИБА (ES)
РУИС Пабло Висенте ЭСКРИБА
Original Assignee
Университат Де Лез Иль Балеар
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Университат Де Лез Иль Балеар filed Critical Университат Де Лез Иль Балеар
Publication of RU2004114229A publication Critical patent/RU2004114229A/ru
Application granted granted Critical
Publication of RU2310445C2 publication Critical patent/RU2310445C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2004114229/15A 2001-10-11 2002-10-09 Применение гидроксиолеиновой кислоты и родственных соединений при производстве лекарственных средств RU2310445C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ESP200102269 2001-10-11
ES200102269A ES2186576B1 (es) 2001-10-11 2001-10-11 Acido 2-hidroxioleico para utilizar como medicamento.

Publications (2)

Publication Number Publication Date
RU2004114229A RU2004114229A (ru) 2005-04-20
RU2310445C2 true RU2310445C2 (ru) 2007-11-20

Family

ID=8499164

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2004114229/15A RU2310445C2 (ru) 2001-10-11 2002-10-09 Применение гидроксиолеиновой кислоты и родственных соединений при производстве лекарственных средств

Country Status (13)

Country Link
US (3) US20050014831A1 (enExample)
EP (1) EP1435235B1 (enExample)
JP (1) JP4737931B2 (enExample)
CN (3) CN101259122B (enExample)
AT (1) ATE322261T1 (enExample)
BR (1) BRPI0213165B8 (enExample)
CA (1) CA2463348C (enExample)
DE (1) DE60210488T2 (enExample)
ES (2) ES2186576B1 (enExample)
MX (1) MXPA04003255A (enExample)
PT (1) PT1435235E (enExample)
RU (1) RU2310445C2 (enExample)
WO (1) WO2003030891A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2513995C2 (ru) * 2009-03-16 2014-04-27 Липофарма Терапьютикс, С.Л. Применение 2-гидроксипроизводных полиненасыщенных жирных кислот в качестве лекарственных препаратов

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2229935B1 (es) * 2003-10-10 2006-10-01 Universitat De Les Illes Balears Utilizacion del acido hidroxioleico y compuestos analagos del mismo como aditivos alimentarios funcionales.
JP2009051732A (ja) * 2005-12-13 2009-03-12 Meiji Seika Kaisha Ltd Ｐｐａｒリガンド活性を有する組成物
CN101570481B (zh) * 2008-04-30 2012-02-01 上海医药工业研究院 一种多羟基长链脂肪酸及其分离提取方法和在抑制芳香化酶活性中的应用
ES2342997B1 (es) * 2008-12-09 2011-06-06 Universitat De Les Illes Balears Alpha derivados de acidos grasos cis-monoinsaturados para ser usados como medicamento.
WO2011089265A1 (en) 2010-01-25 2011-07-28 Bridge Bioresearch Plc Use of fatty acid compounds for lowering blood glucose levels
CN101985420B (zh) * 2010-01-29 2014-04-30 苏州润新生物科技有限公司 油酸酯及其制备方法和在制备用于治疗高血压及其并发症的药物中的应用
ES2401629B1 (es) * 2011-10-07 2014-03-04 Universitat De Les Illes Balears Enantiómeros de 2-hidroxiderivados de ácidos grasos y su uso como medicamentos.
WO2013108428A1 (ja) * 2012-01-19 2013-07-25 日本水産株式会社 食欲抑制剤
WO2013132092A1 (en) 2012-03-09 2013-09-12 Pensieve International Plc Use of monounsaturated fatty acid compounds for controlling the body weight of a dog or a cat
ES2734554T3 (es) * 2012-09-26 2019-12-10 Tangent Reprofiling Ltd Combinación de benzo(iso)oxazolpiperidinas con ácido linoleico conjugado
GB201217296D0 (en) 2012-09-27 2012-11-14 Alta Innovations Ltd Method of treatment and/or prevention
RU2679443C2 (ru) * 2014-10-21 2019-02-11 Университат Де Лес Ильес Балеарс Способ синтеза гидрокситриглицеридов и их применение для профилактики и лечения заболеваний
US10756968B2 (en) 2015-01-26 2020-08-25 Rapid7, Inc. Network resource management devices methods and systems

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987004926A2 (en) * 1986-02-14 1987-08-27 Nagy Adly Habib Method of modifying the lipid structure of cell membranes and pharmaceutical compositions for use therein
WO1999058121A1 (en) * 1998-05-08 1999-11-18 Thia Medica As Novel fatty analogues for the treatment of obesity, hypertension and fatty liver

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61297A (ja) * 1984-06-12 1986-01-06 日本油脂株式会社 オレイン酸の製造法
JPS6344843A (ja) * 1986-08-13 1988-02-25 Kao Corp 油中水中油型乳化油脂組成物
CN1035925C (zh) * 1988-11-16 1997-09-24 许正 亲细胞非均质分子脂质的制备方法
US5422371A (en) * 1992-05-27 1995-06-06 Arch Development Corp. Methods and compositions for inhibiting 5α-reductase activity
CN1118228A (zh) * 1995-03-16 1996-03-13 姜训书 松籽果酱
CN1118218A (zh) * 1995-03-16 1996-03-13 姜训书 松籽油的制作方法及松籽保健食用油
GB9506837D0 (en) * 1995-04-03 1995-05-24 Scotia Holdings Plc Triglycerides
ES2192221T3 (es) * 1995-10-30 2003-10-01 Oleoyl Estrone Developments S Monoesteres de oleato de estrogenos para el tratamiento de la obesidad o el sobrepeso.
US5856537A (en) * 1996-06-26 1999-01-05 The Scripps Research Institute Inhibitors of oleamide hydrolase
DE19727636C1 (de) * 1997-06-28 1998-11-19 Rwe Dea Ag Verfahren zur Herstellung von 2-Alkylcarbonsäuren
CN1212867A (zh) * 1997-09-29 1999-04-07 宋凤亭 防治心脑血管疾病的组合物
EP0948963B1 (en) * 1998-01-21 2003-05-07 Fideline Pig appeasing pheromones to decrease stress, anxiety and aggressiveness
US6214875B1 (en) * 1998-04-14 2001-04-10 Zhenhua Yang Anticancer effects of specific branched-chain fatty acids and related production process
GB2389788B (en) * 2000-12-23 2005-07-20 Univ Creighton Methods for inducing apoptosis and inhibiting proliferation in cancer cells
DE10130491A1 (de) * 2001-06-25 2003-04-17 Heirler Horst Verwendung von mittelkettigen Triglyceriden zur Prävention und Therapie von Adipositas

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987004926A2 (en) * 1986-02-14 1987-08-27 Nagy Adly Habib Method of modifying the lipid structure of cell membranes and pharmaceutical compositions for use therein
WO1999058121A1 (en) * 1998-05-08 1999-11-18 Thia Medica As Novel fatty analogues for the treatment of obesity, hypertension and fatty liver

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BANNI S. et al. Vaccenic acid feeding increases tissue levels of conjugated linoleic acid and suppresses development of premalignant lesions in rat mammary gland. Nutr Cancer. 2001; 41(1-2):91-7. *
ДЖЕНКИНС Г., Хартунг У., «Химия органических лекарственных препаратов», М.: Государственное издательство иностранной литературы, 1949, стр.232-233. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2513995C2 (ru) * 2009-03-16 2014-04-27 Липофарма Терапьютикс, С.Л. Применение 2-гидроксипроизводных полиненасыщенных жирных кислот в качестве лекарственных препаратов

Also Published As

Publication number Publication date
CN100471492C (zh) 2009-03-25
ES2261752T3 (es) 2006-11-16
CN101259122A (zh) 2008-09-10
US20090082446A1 (en) 2009-03-26
US20110136906A1 (en) 2011-06-09
CN1688302A (zh) 2005-10-26
BR0213165A (pt) 2004-09-14
CA2463348C (en) 2011-04-05
DE60210488T2 (de) 2006-12-14
DE60210488D1 (de) 2006-05-18
US8778995B2 (en) 2014-07-15
BRPI0213165B8 (pt) 2021-05-25
CA2463348A1 (en) 2003-04-17
ATE322261T1 (de) 2006-04-15
EP1435235A1 (en) 2004-07-07
US20050014831A1 (en) 2005-01-20
JP4737931B2 (ja) 2011-08-03
US7851507B2 (en) 2010-12-14
MXPA04003255A (es) 2005-01-25
RU2004114229A (ru) 2005-04-20
CN101259121A (zh) 2008-09-10
ES2186576A1 (es) 2003-05-01
JP2005527479A (ja) 2005-09-15
EP1435235B1 (en) 2006-04-05
CN101259121B (zh) 2011-04-06
WO2003030891A1 (es) 2003-04-17
BRPI0213165B1 (pt) 2018-01-23
PT1435235E (pt) 2006-08-31
CN101259122B (zh) 2011-04-06
ES2186576B1 (es) 2004-09-16

Similar Documents

Publication Publication Date Title
US7851507B2 (en) Use of hydroxyoleic acid and related compounds in the manufacture of drugs
AU2016238970B2 (en) Use of derivatives of polyunsaturated fatty acids as medicaments
JP6038841B2 (ja) 腫瘍性疾患の治療のためのドコサヘキサエン酸グリセリドの使用
KR20030016306A (ko) 지방산의 치료용 조합
JP2024010082A (ja) オートファジーおよびリポファジーを調節するためのβ－ヒドロキシ－β－メチルブチレート（ＨＭＢ）の組成物および使用方法
CN100496478C (zh) 羟基油酸及相关化合物作为功能性食品添加剂的应用
US20100022444A1 (en) Combination therapy for modulation of activity and development of cells and tissues
JP3816545B2 (ja) 人工透析患者の皮膚そう痒症治療組成物及び副甲状腺機能亢進症治療組成物
JP2018177738A (ja) Ｔｒｐｖ４活性抑制剤
JP5507445B2 (ja) ２−アミノフェノール又はその誘導体を有効成分とする骨形成促進剤
Cynober How Can We Modulate Cytokine
JP5923404B2 (ja) Ｔｒｐｖ４活性抑制剤
JP2005247871A (ja) 人工透析患者の副甲状腺機能亢進症治療組成物
RU97115999A (ru) Аминокислотные композиции и их применение в лечебном питании
TW200800165A (en) Breast cancer cell inhibiting agents
JP2007137838A (ja) オキソリン化合物を有効成分とする医薬